Exelixis Inc. (EXEL)

19.54
0.03 0.15
NASDAQ : Health Technology
Prev Close 19.57
Open 19.64
Day Low/High 19.46 / 20.04
52 Wk Low/High 13.42 / 25.31
Volume 5.01M
Avg Volume 2.52M
Exchange NASDAQ
Shares Outstanding 302.91M
Market Cap 5.84B
EPS 2.30
P/E Ratio 9.45
Div & Yield N.A. (N.A)

Latest News

Exelixis And Aurigene Enter Into Exclusive Collaboration, Option And License Agreement To Discover And Develop Novel Therapies For Cancer

Exelixis And Aurigene Enter Into Exclusive Collaboration, Option And License Agreement To Discover And Develop Novel Therapies For Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology company focused on oncology...

Exelixis To Release Second Quarter 2019 Financial Results On Wednesday, July 31, 2019

Exelixis To Release Second Quarter 2019 Financial Results On Wednesday, July 31, 2019

Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2019 financial results will be released on Wednesday, July 31, 2019 after the markets close.

Exelixis Updates Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors

Exelixis Updates Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors

Exelixis, Inc. (NASDAQ: EXEL) today announced that two original cohorts are being expanded and four new cohorts are being added to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®)...

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Exelixis Announces Webcasts Of Investor Conference Presentations In June 2019

Exelixis Announces Webcasts Of Investor Conference Presentations In June 2019

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following three investor conferences in June 2019: William Blair 39 th Annual Growth Stock Conference: Exelixis is scheduled to present at 5:00 PM EDT / 2:00 PM PDT...

Http://www.iconictherapeutics.com

Http://www.iconictherapeutics.com

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics, Inc.

Exelixis Announces Webcasts Of Investor Conference Presentations On May 21, 2019

Exelixis Announces Webcasts Of Investor Conference Presentations On May 21, 2019

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York: UBS Global Healthcare Conference: Exelixis is scheduled to present at 10:00 AM EDT / 7:00 AM...

Exelixis' Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets In Japan

Exelixis' Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets In Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") has launched MINNEBRO ® (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

Can't Keep the Winners Down: Cramer's 'Mad Money' Recap (Thursday 5/9/19)

Can't Keep the Winners Down: Cramer's 'Mad Money' Recap (Thursday 5/9/19)

Jim Cramer says that sometimes it takes a really bad day to reveal the true winning stocks.

Cisco Systems, Sunrun, Zebra Technologies: 'Mad Money' Lightning Round

Cisco Systems, Sunrun, Zebra Technologies: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cisco Systems, Sunrun, Zebra Technologies, EQT Midstream Partners, Exelixis, The Trade Deck and more.

Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) Of Cabozantinib In Combination With Nivolumab And Ipilimumab Versus Nivolumab And Ipilimumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) Of Cabozantinib In Combination With Nivolumab And Ipilimumab Versus Nivolumab And Ipilimumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ: EXEL) today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with nivolumab (Opdivo®) and ipilimumab (Yervoy®) versus nivolumab and ipilimumab in patients with...

Exelixis Announces First Quarter 2019 Financial Results And Provides Corporate Update

Exelixis Announces First Quarter 2019 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Exelixis' Partner Takeda Announces Filing Of New Drug Application In Japan For CABOMETYX® (Cabozantinib) For Advanced Renal Cell Carcinoma

Exelixis' Partner Takeda Announces Filing Of New Drug Application In Japan For CABOMETYX® (Cabozantinib) For Advanced Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of cabozantinib in Japan, has applied to the Japanese Ministry of Health, Labor...

Exelixis To Release First Quarter 2019 Financial Results On Wednesday, May 1, 2019

Exelixis To Release First Quarter 2019 Financial Results On Wednesday, May 1, 2019

Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2019 financial results will be released on Wednesday, May 1, 2019 after the markets close.

Exelixis To Present At The 18th Annual Needham Healthcare Conference On April 10, 2019

Exelixis To Present At The 18th Annual Needham Healthcare Conference On April 10, 2019

Exelixis, Inc. (NASDAQ: EXEL) today announced that Christopher J.

How I Use Options to Mitigate Risk and Create Income

How I Use Options to Mitigate Risk and Create Income

Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.

Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis, Inc. (NASDAQ: EXEL) today announced that the company will be presenting at the following investor conferences in March: Cowen & Co.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Fitbit, Moderna, Tilray, Exelixis, Maxar Technology, International Paper and more.

Exelixis Rises as Fourth-Quarter Earnings Beat Estimates

Exelixis Rises as Fourth-Quarter Earnings Beat Estimates

The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.

These 'Small Ball' Names Will Outperform the Market in 2019

These 'Small Ball' Names Will Outperform the Market in 2019

Investors are already more focused on what lies ahead when Q1 results start in early April.

Exelixis Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Exelixis To Initiate Phase 1 Clinical Development Of XL092, First New Compound To Enter The Clinic From Reinitiated Discovery Efforts

Exelixis To Initiate Phase 1 Clinical Development Of XL092, First New Compound To Enter The Clinic From Reinitiated Discovery Efforts

Exelixis, Inc. (Nasdaq: EXEL) today announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the clinic following the company's reinitiation of drug discovery activities.

Exelixis To Present At The Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 On February 14, 2019

Exelixis To Present At The Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 On February 14, 2019

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

TheStreet Quant Rating: B- (Buy)